Amarin Pharma, Inc. et al v. Hikma Pharmaceuticals USA Inc., et al.

  1. January 06, 2022

    Generics Catch A Break With Hikma's Skinny Label Win

    Generic-drug makers have spent more than a year voicing concerns that the Federal Circuit's holding in GlaxoSmithKline v. Teva threatened their ability to sell generic drugs that leave patent-protected indications off the label, but a Delaware federal judge this week quelled some of those fears by quickly throwing out a challenge to such "skinny labels."

  2. January 04, 2022

    Hikma Beats Amarin's 'Skinny Label' Patent Suit

    Hikma Pharmaceuticals USA Inc.'s generic heart drug does not infringe three patents underlying Amarin Pharma Inc.'s drug Vascepa, a Delaware federal judge ruled Tuesday, breaking with the recommendation from a magistrate judge.

  3. August 20, 2021

    Generics Group Says 'Skinny Label' Suit Should Not Proceed

    The Association for Accessible Medicines has urged a Delaware federal judge to reject part of a magistrate judge's report and recommendation not to dismiss Amarin Pharma Inc.'s infringement suit against Hikma Pharmaceuticals USA Inc. over its heart drug Vascepa, saying that if the suit goes forward, patients will be forced to pay higher prices for branded drugs.

  4. August 03, 2021

    Hikma Should Face Amarin's Patent Suit, Magistrate Says

    Hikma Pharmaceuticals should not be able to dodge a lawsuit claiming it encouraged doctors to prescribe its generic version of the heart drug Vascepa for uses covered by a series of Amarin patents, a Delaware federal magistrate judge says.